Jim Simons Adma Biologics, Inc. Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 2,007,035 shares of ADMA stock, worth $22.4 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

2,007,035

Previous 1,057,935 89.71%

Holding current value

$22.4 Million

Previous $4.78 Million 177.0%

% of portfolio

0.02%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$4.4 - $6.74 $4.18 Million - $6.4 Million	949,100 Added 89.71%	2,007,035 $13.2 Million
Q4 2023 Feb 13, 2024	SELL	$3.08 - $4.52 $1.04 Million - $1.53 Million	-338,620 Reduced 24.25%	1,057,935 $4.78 Million
Q3 2023 Nov 14, 2023	BUY	$3.47 - $4.61 $634,385 - $842,800	182,820 Added 15.06%	1,396,555 $5 Million
Q2 2023 Aug 11, 2023	BUY	$3.12 - $4.22 $750,360 - $1.01 Million	240,500 Added 24.71%	1,213,735 $4.48 Million
Q1 2023 May 12, 2023	BUY	$3.01 - $3.87 $834,672 - $1.07 Million	277,300 Added 39.85%	973,235 $3.22 Million

Q4 2022 Feb 13, 2023	BUY	$2.47 - $3.88 $142,111 - $223,235	57,535 Added 9.01%	695,935 $2.7 Million
Q3 2022 Nov 14, 2022	SELL	$2.03 - $2.86 $176,812 - $249,106	-87,100 Reduced 12.01%	638,400 $1.55 Million
Q2 2022 Aug 12, 2022	BUY	$1.43 - $2.2 $284,284 - $437,360	198,800 Added 37.74%	725,500 $1.44 Million
Q1 2022 May 13, 2022	BUY	$1.28 - $1.83 $227,584 - $325,374	177,800 Added 50.96%	526,700 $964,000
Q4 2021 Feb 11, 2022	BUY	$1.09 - $1.66 $124,151 - $189,074	113,900 Added 48.47%	348,900 $492,000
Q3 2021 Nov 12, 2021	BUY	$1.13 - $1.65 $67,092 - $97,967	59,374 Added 33.81%	235,000 $266,000
Q2 2021 Aug 13, 2021	BUY	$1.51 - $2.07 $265,195 - $363,545	175,626 New	175,626 $281,000

Others Institutions Holding ADMA

# of Institutions

224

Shares Held

174M

Call Options Held

85.5K

Put Options Held

12.8K

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $2.2B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account